

Agalsidase Beta (FABRAZYME) **Infusion Therapy Plan Orders**

Printed Name:

Page 1 of 3

Name:
Member I.D. #
Date of Birth

Instructions to Provider

Review orders and note any changes. All orders with 🗹 will be placed unless otherwise noted. Please fax completed order

				be receiving treatment (see fax numbe orders via usual method. Lab monitori	
physiciar	n.		•		, , , , , , , , , , , , , , , , , , , ,
Please c	omplete	all of the follow			
			Diagnosis:	··	
Order Date:			ICD-10 code (REQUIRED):	
Weight:		ka	ICD-10 descri	otion	
Genera	l Plan	Communicat	tion		
				sample for antibody and GL-3 enzym	e testing. Genzyme provides kit with
		ons and blood	collection tubes	s. Kits can be ordered from Genzyme	by any staff member at 1-800-745-
	4447.				
•	Next blo	od/enzyme co	llection date		
Infusio	n Ther	ару			
	Agals	idase Beta (I		IV infusion in 0.9% Sodium Ch	
			g (will be roun	ded the nearest 5 mg) = 1 mg/kg x	weight (kg)
		e: Intravenous	7 O o l-	- 0	
	•	•	d every 2 week		
	Intusi		sed upon patier		
			35	Minimum Total Volume (mL) 50	
			_ 70	100	
			- 100	250	
			100	500	
	Initial Interro sympt tolera each : Maxim If infu 1) r Note	upt or decrease toms and/or aft nee to the infus subsequent infusion rate sion-related restroyended in STOP infusion nedications pe	e rate in the ever ter administrationsion is establish fusion. e: Patients <30 kg action: n immediately; r hypersensitivit	ed 0.25 mg/minute. ent of an infusion reaction; may be reson of antipyretics, antihistamines, and sed, rate may be increased in increments: 0.25 mg/minute; patients ≥30 kg: Infuse: 2) Increase primary infusion to wide one of the protocol; 4) Notify MD then:	/or steroids. After patient ents of 0.05-0.08 mg/minute with over at least 1.5 hours. open rate; 3) Administer PRN
Pre-Me					
Ø	Dose May cetirizing Dose	also be given one (ZYRTEC) to: 10:2:10 mg	oute: Oral Fre once as needed ablet oute: Oral	equency: Once, 30 minutes prior to ag during infusion for fever, headache, of tes prior to agalsidase beta (Fabrazyr	or myalgia.
Provide	er Sign	ature:			Date:

Phone: _____ Fax: ____



Agalsidase Beta (FABRAZYME) **Infusion Therapy Plan Orders**

Page 2 of 3

Name:
Member I.D. #
Date of Birth

No routine pre-medications necessary.	Above pre-meds	may be	given if	patient has	reaction and	requires	pre-
medications for future doses.							

IV Line Care

0.9% sodium chloride infusion 250 mL

Rate: 30 mL/hr Route: Intravenous Frequency: Run continuously to keep vein open

Start peripheral IV if no central line

Infusion Reaction Meds

☑ Acetaminophen Tab 650 mg (TYLENOL)

Dose: 650 mg Route: Oral Frequency: EVERY 4 HOURS AS NEEDED for fevers greater than 100.4 F, myalgias, arthralgias or headache.

albuterol (PROVENTIL) nebulizer solution 0.083%

Dose: 2.5 mg Route: Nebulization Frequency: PRN for shortness of breath/wheezing

☐ diphenhydrAMINE (BENADRYL) injectable

Dose: 25 mg Route: Intravenous Frequency: Once PRN, May repeat x1 for urticaria, pruritus, shortness of breath. May repeat in 15 minutes if symptoms not resolved.

☑ EPINEPHrine (EpiPen) 0.3 mg/0.3 mL IM Auto-Injector

Route: Intramuscular Frequency: Once PRN for anaphylaxis. Inject into lateral thigh Dose: 0.3 mg and hold for 10 seconds. Massage the injected area. Use for patients weighing greater than 27.3 kg (60 lbs). Use amp and 1.5 inch needle for patients with BMI greater than 30. Notify physician if administered.

☑ MethylPREDNISolone Sod Succ (PF) Inj 125 mg (SOLU-Medrol PF). Dose: 125 mg Route: IV push Frequency: Once PRN for hypersensitivity reaction. Notify MD upon giving medication.

Lab Review for Nursing

Ensure baseline lab (e.g., SCr) is drawn within 3 months of initial treatment if provider has ordered.

Nursing Orders

- ~ Anaphylaxis (e.g., hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea) has been reported in patients. Discontinue infusion if any of these symptoms are observed and report to MD for additional instructions.
- ~ Infusion related reaction: STOP infusion immediately, begin primary solution at wide open rate, notify MD, begin monitoring vital signs, and administer prn medication for infusion reaction; once symptoms have resolved, consult with MD on rate to resume infusion.
- ~ Monitor patient for at least one hour after medication has infused for evidence of adverse reaction.
- ~ Review discharge medications, instructions, and future appointments.
- ~ Following infusion, flush line with Normal Saline until all drug is infused.
- ~ Discontinue IV line when therapy complete and patient stabilized.

References

Fabrazyme Prescribing Information Revised May 2019

Kaiser Permanente Infusion Locations

Bellevue Medical Center

11511 NE 10th St. Bellevue. WA 98004

Fax: 425-502-3512 Phone: 425-502-3510

Capitol Hill Medical Center

201 16th Ave E, Seattle WA 98112

Fax: 206-326-2104 Phone: 206-326-3109 Riverfront Medical Center - Spokane

W 322 North River Drive, Spokane, WA 99201 Fax: 509-324-7168 Phone: 509-241-2073

Silverdale Medical Center

10452 Silverdale Way NW, Silverdale, WA 98383 Fax: 360-307-7421 Phone: 360-307-7316

Provider Signature:	Date:
Printed Name:	Phone: Fax:
	HIM Revision Date: 8/22/2022 Kaiser Permanente <reference#12254></reference#12254>



Agalsidase Beta (FABRAZYME) **Infusion Therapy Plan Orders**

Page 3 of 3

Name:
Member I.D. #
Date of Birth

Everett Medical Center

2930 Maple St, Everett, WA 98201

Fax: 425-261-1578 Phone: 425-261-1566

Olympia Medical Center

700 Lilly Road N.E., Olympia, WA 98506 Fax: 360-923-7106 Phone: 360-923-7164

Tacoma M	edical	Center
----------	--------	--------

209 Martin Luther King Jr Way, Tacoma, WA 98405 Fax: 253-383-6262 Phone: 253-596-3666

Provider Signature:		Date:	
Printed Name:	Phone:	Fax:	

нім